^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Nubeqa (darolutamide) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6271 / 6 - Hormone receptor inhibition as a strategy for radiosensitization of breast cancer
Published date:
05/15/2020
Excerpt:
AR inhibition with enzalutamide, apalutamide, and darolutamide showed limited single agent growth inhibition efficacy in AR+ TNBC and AR+, ER+ breast cancer cell lines (IC50 > 10 μM).
